Evidence map›Paper›PMID 42846329›Full record

ArticleFrontiers in pharmacology2026

Functional-genomic prioritization identifies

Zhouchun Chen, Tianran Chai, Meichen Liu, Haigang Wu, Yangjie Li, Wenyuan Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhouchun Chen *School of Medicine, Xinjiang University of Science and Technology, Korla, Xinjiang, China.
Tianran Chai *School of Life Sciences, Henan University, Kaifeng, Henan, China.
Meichen Liu *School of Basic Medical Science, Henan University, Kaifeng, Henan, China.
Haigang WuSchool of Life Sciences, Henan University, Kaifeng, Henan, China.
Yangjie LiSchool of Medicine, Xinjiang University of Science and Technology, Korla, Xinjiang, China.
Wenyuan YangSchool of Life Sciences, Henan University, Kaifeng, Henan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Acute myeloid leukemia (AML) depends in part on transcriptional and epigenetic programs that can be difficult to target with conventional small molecules. RNA interference provides a potential approach to perturb such vulnerabilities, but target selection and intracellular siRNA delivery remain major challenges. Methods: Public dependency datasets and primary AML and normal hematopoietic expression resources were integrated to prioritize candidate RNAi vulnerabilities. A T22 peptide-functionalized lipid nanoparticle (TLNP) formulation carrying siMED12 was evaluated in OCI-AML3 cells, with RT-qPCR and CCK-8 validation in THP-1 cells. A systemic OCI-AML3 mouse model was used for exploratory assessment of survival and tolerability. Results: Conclusion: Integrated functional-genomic prioritization identified

Indexed as

acute myeloid leukemiaCXCR4functional genomicslipid nanoparticlesMED12RNA interferencesiRNAT22 peptide

Identifiers

PMID42846329
PMCPMC13642598

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.